Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Gerard Zalcman, ESMO 2022: IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab in advanced non-small cell lung cancer

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 14th 2022

First-line immunotherapy is a standard treatment for patients with advanced non-small cell lung cancer. Prof. Gerard Zalcman (Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Institute of Cancer AP-HP Nord, Paris, France) joins touchONCOLOGY to discuss the IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab, aiming to assess if 6-months nivolumab/ipilimumab duration was equivalent to continuation until progression in patients with disease control.

The abstract entitled ‘Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial‘ Abstract 972O, was presented at European Society for Medical Oncology (ESMO) 2022.

Questions:

  1. What is the basis of the standard 2 years duration of immunotherapy with advanced NSCLC and no targetable mutation? (0:21)
  2. What were the aims, design and eligibility criteria of your study? (0:50)
  3. What were the findings of the study in terms of disease progression? (2:04)
  4. What were the reasons for the premature halt of the trial? (2:44)
  5. What further investigation is planned? (3:02)

Disclosures: Gerard Zalcman receives grant/research support from Fondation ROCHE (France); is on the advisory board for BMS, Pfizer, Astra-Zeneca, Takeda, Inventiva, and PAredox therapeuticals; and receives honoraria/honorarium from BMS, Astra-Zeneca, and Pfizer.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of ESMO 2022

Access more lung cancer content here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup